Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 5/20 | 0.51 |
| ▸ | ACACB | O00763 | 5/20 | 0.46 |
| ▸ | OGA | O60502 | 1/20 | 0.39 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21016975 | 0.83 | HCAR3 (0.47) | HCAR3ACACBOGADEGS1PTK2 | |
| SCHEMBL21016981 | 0.82 | ACACB (0.42) | ACACBOGADEGS1PTK2LMNA | |
| SCHEMBL23768085 | 0.81 | POLB (0.51) | HCAR3ACACBLMNAL3MBTL1MAPT | |
| SCHEMBL26547631 | 0.78 | HCAR3 (0.51) | HCAR3OGADEGS1LMNAPDE10A | |
| SCHEMBL26798707 | 0.77 | HCAR3 (0.50) | HCAR3DEGS1LMNAMEN1TP53 | |
| SCHEMBL608849 | 0.75 | ACACB (0.44) | ACACBOGAPTK2LMNAPOLB | |
| SCHEMBL14808848 | 0.75 | ACACB (0.44) | ACACBOGALMNAL3MBTL1MEN1 | |
| SCHEMBL27254652 | 0.73 | ACACB (0.54) | ACACBMAPTPOLB | |
| SCHEMBL2254246 | 0.73 | ACACB (0.42) | ACACBOGAMAPTKMT2AKDM4E | |
| SCHEMBL13312903 | 0.73 | HCAR3 (0.49) | HCAR3LMNAMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253554-A1 | SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253554-A1 | SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS | TYK2, JAK3, JAK2 | HCAR3 1016/4885ACACB 4458/4885OGA 3965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.